Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Alamos Gold is generating record cash flow in a high gold-price environment, but AGI is also asking investors to underwrite a capital-heavy Island Gold District expansion, a 2026 cost decline, hedge cleanup and a path toward materially higher Canadian producti
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Pfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
OpenHims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
Openagilon health turned in a stronger Q1 after a brutal FY2025 reset, but the thesis still depends on whether member exits, payor discipline, ACO contribution and CEO execution can hold up against Medicare Advantage medical-cost trend.
OpenAeroméxico has premium demand, loyalty scale and record-margin evidence after its U.S. listing, but the Delta JCA, MEX constraints, fuel, FX, engine issues and a negative equity balance sheet make the setup high risk.
OpenAduro has a real cash runway after two U.S. offerings, but the decision point is whether Hydrochemolytic Technology can move from customer trials and pilot work into demonstration-scale economics before burn and dilution absorb the runway.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenOfficial-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.
OpenTag facets appear after tag usage counts are rebuilt.